125 related articles for article (PubMed ID: 15977100)
1. Ovarian function after radioiodine therapy in patients with thyroid cancer.
Souza Rosário PW; Alvarenga Fagundes T; Villas-Boas Fagundes AS; Barroso AL; Lamego Rezende L; Lanza Padrão E; Guimarães VC; Horta AC; Franco M; Purisch S
Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):331-3. PubMed ID: 15977100
[TBL] [Abstract][Full Text] [Related]
2. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine.
Pacini F; Gasperi M; Fugazzola L; Ceccarelli C; Lippi F; Centoni R; Martino E; Pinchera A
J Nucl Med; 1994 Sep; 35(9):1418-22. PubMed ID: 8071685
[TBL] [Abstract][Full Text] [Related]
3. BGP serum levels in patients with thyroid carcinoma before and 4-14 weeks after radioiodine therapy.
Stracke H; Federlin K
Exp Clin Endocrinol; 1993; 101(3):186-8. PubMed ID: 8223990
[TBL] [Abstract][Full Text] [Related]
4. Menstrual cycle disorders after therapy with iodine-131.
Sioka C; Kouraklis G; Zafirakis A; Manetou A; Dimakopoulos N
Fertil Steril; 2006 Sep; 86(3):625-8. PubMed ID: 16782093
[TBL] [Abstract][Full Text] [Related]
5. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
6. Testicular function after radioiodine therapy for thyroid carcinoma.
Wichers M; Benz E; Palmedo H; Biersack HJ; Grünwald F; Klingmüller D
Eur J Nucl Med; 2000 May; 27(5):503-7. PubMed ID: 10853804
[TBL] [Abstract][Full Text] [Related]
7. High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring.
Bal C; Kumar A; Tripathi M; Chandrashekar N; Phom H; Murali NR; Chandra P; Pant GS
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):449-55. PubMed ID: 16095849
[TBL] [Abstract][Full Text] [Related]
8. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
9. [Changes in the blood picture after radioiodine therapy of thyroid cancer].
Grünwald F; Schomburg A; Menzel C; Steinecker S; Späth G; Bockisch A; Fimmers R; Hotze AL; Biersack HJ
Med Klin (Munich); 1994 Oct; 89(10):522-8. PubMed ID: 7808352
[TBL] [Abstract][Full Text] [Related]
10. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study.
Zettinig G; Hanselmayer G; Fueger BJ; Hofmann A; Pirich C; Nepp J; Dudczak R
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1428-32. PubMed ID: 12397459
[TBL] [Abstract][Full Text] [Related]
11. [Metastases of a medullary carcinoma of the thyroid (follicular variant). Diagnosis and therapy using radioiodine].
Ruhlmann J; Vogel J; Bockisch A; Biersack HJ
Dtsch Med Wochenschr; 1987 Jul; 112(30):1170-2. PubMed ID: 3608841
[TBL] [Abstract][Full Text] [Related]
12. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies.
Garsi JP; Schlumberger M; Rubino C; Ricard M; Labbé M; Ceccarelli C; Schvartz C; Henri-Amar M; Bardet S; de Vathaire F
J Nucl Med; 2008 May; 49(5):845-52. PubMed ID: 18413399
[TBL] [Abstract][Full Text] [Related]
14. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
15. [Genetic risk after high dose radioiodine therapy with regard to gonadal dose].
Ehrenheim C; Hauswirth C; Fitschen J; Martin E; Oetting G; Hundeshagen H
Nuklearmedizin; 1997 Aug; 36(5):157-66. PubMed ID: 9380527
[TBL] [Abstract][Full Text] [Related]
16. Menstrual cycle length in relation to antimüllerian hormone and follicle-stimulating hormone.
Rashidi BH; Abediasl Z; Tehraninejad ES; Shariat M; Mahdavi A
J Reprod Med; 2009 May; 54(5):315-8. PubMed ID: 19517697
[TBL] [Abstract][Full Text] [Related]
17. Testicular function after radioiodine therapy in patients with thyroid cancer.
Rosário PW; Barroso AL; Rezende LL; Padrão EL; Borges MA; Guimarães VC; Purisch S
Thyroid; 2006 Jul; 16(7):667-70. PubMed ID: 16889490
[TBL] [Abstract][Full Text] [Related]
18. Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis.
Joseph LJ; Bhartiya US; Raut YS; Kand P; Hawaldar RW; Nair N
Mutat Res; 2009 Apr; 675(1-2):35-40. PubMed ID: 19386245
[TBL] [Abstract][Full Text] [Related]
19. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity.
Rosário PW; Borges MA; Purisch S
J Nucl Med; 2008 Nov; 49(11):1776-82. PubMed ID: 18927337
[TBL] [Abstract][Full Text] [Related]
20. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
